Skip to content
- Van der Noll R, et al. Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities. Cancer Treat Rev 2013; 39(6):664-72.
- Ho WL, et al. The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists? Acta Ophthalmol 2012.
- Renouf DJ, et al. Ocular toxicity of targeted therapies. J Clin Oncol 2012;30(26):3277-86.
- Saint-Jean A, et al. Ocular adverse events of systemic inhibitors of the epidermal growth factor receptor: report of 5 cases. Ophtalmology 2012;119(9):1798-802.
- Borkar DS, et al. Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review. Support Care Cancer 2013;21(4):1167-74.
- Huillard O, et al. Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review. Eur J Cancer 2014;50(3):638-48.
- Agustoni F, et al. Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders. Cancer Treat Rev 2014;40(1):197-203.